HOPE-3 was designed to assess if reducing BP and/or LDL-C would reduce cardiovascular events in study participants at intermediate risk with no prior cardiovascular events.
The researchers conducted a comprehensive systematic review and meta-analysis comparing mortality and severe adverse events associated with receipt vs nonreceipt of ACEIs or ARBs among patients with COVID-19.
The authors explore the etiology and clinical presentation of primary and secondary aldosteronism as well as medical and surgical treatment options.
This action was in response to an executive order issued on August 6, 2020 aimed at protecting the public against outbreaks of emerging diseases and chemical, biological, radiological, and nuclear threats.
Reduction comparable to adherence to Mediterranean diet or moderate reduction in salt
Three specific goals can drive change in hypertension control in the United States
The aim of the study was to analyze antihypertensive utilization patterns among patients with uncontrolled hypertension despite receiving therapy.
Patients who undergo RYGB are less likely to need antihypertensive medications at 3 years compared with those who manage their blood pressure with medical therapy alone.
Patients who undergo RYGB are less likely to need antihypertensive medications at 3 years compared with those who manage their blood pressure with medical therapy alone.
Self-measured BP monitoring at home may be a cost-effective way to improve the diagnosis and management of patients with hypertension.
